Media headlines about Pacific Biosciences of California (NASDAQ:PACB) have trended positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.37 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.7369163074732 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Humana Inc. (HUM) registers a price flow of 0.21% while Pacific Biosciences of California, Inc. (PACB) finishes with … - Stocks Gallery (stocksgallery.com)
- Stock Moving Towards 52-Week Low Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Sparta Review (spartareview.com)
- Weekly Performance of Healthcare stock: Pacific Biosciences of California, Inc. (PACB) stock fluctuated 1.57% higher - Street Observer (press release) (streetobserver.com)
- Pacific Biosciences Second Quarter 2017 Financial Results Call (biospace.com)
Several analysts recently commented on the company. BidaskClub lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. ValuEngine lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th. Zacks Investment Research lowered Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th. Finally, Cantor Fitzgerald set a $8.00 price objective on Pacific Biosciences of California and gave the stock a “buy” rating in a report on Thursday, April 27th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company’s stock. Pacific Biosciences of California presently has an average rating of “Hold” and a consensus price target of $10.00.
Shares of Pacific Biosciences of California (NASDAQ:PACB) opened at 3.22 on Wednesday. The company has a 50 day moving average price of $3.42 and a 200 day moving average price of $4.28. The company’s market cap is $301.23 million. Pacific Biosciences of California has a one year low of $3.08 and a one year high of $9.50.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
